Farallon Capital Partners L.P. 13D and 13G filings for Agios Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:40 pm Purchase | 2024-09-30 | 13G | Agios Pharmaceuticals, Inc. AGIO | Farallon Capital Partners L.P. | 5,660,866 9.900% | 1,493,264 (+35.83%) | Filing |
| 2024-02-08 11:39 am Purchase | 2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | Farallon Capital Partners L.P. | 4,167,602 7.500% | 206,000 (+5.20%) | Filing |
| 2023-11-09 5:18 pm Purchase | 2023-10-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | Farallon Capital Partners L.P. | 3,961,602 7.100% | 3,961,602 (New Position) | Filing |